Efficacy	B:C1707887
and	O
safety	O
of	O
"	O
unboosting	O
"	O
atazanavir	O
in	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	O
DF	I:C1099776
.	O

Efficacy	O
and	O
safety	B:C1705187
of	O
"	O
unboosting	O
"	O
atazanavir	O
in	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	O
DF	I:C1099776
.	O

Efficacy	O
and	O
safety	O
of	O
"	O
unboosting	O
"	O
atazanavir	B:C1145759
in	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	O
DF	I:C1099776
.	O

Efficacy	O
and	O
safety	O
of	O
"	O
unboosting	O
"	O
atazanavir	O
in	O
a	O
randomized	B:C0206035
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	O
DF	I:C1099776
.	O

Efficacy	O
and	O
safety	O
of	O
"	O
unboosting	O
"	O
atazanavir	O
in	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	O
DF	I:C1099776
.	O

Efficacy	O
and	O
safety	O
of	O
"	O
unboosting	O
"	O
atazanavir	O
in	O
a	O
randomized	O
controlled	I:C0206035
trial	I:C0206035
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
receiving	O
tenofovir	B:C1099776
DF	I:C1099776
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	B:C1145759
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	B:C1145759
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	B:C1145759
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	B:C0292818
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	B:C0292818
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
atazanavir	O
)	O
among	O
HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
receiving	O
atazanavir	O
/	O
ritonavir	O
(	O
ritonavir	O
)	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
(	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	B:C1168369
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	B:C1168369
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	B:C0220908
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	B:C0040808
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	B:C1145759
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	B:C0034656
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	B:C1145759
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	B:C0292818
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	B:C1145759
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

HIV	O
-	I:C0019693
infected	I:C0019693
adults	O
with	O
viral	O
load	I:C1168369
(	O
viral	O
load	I:C1168369
)	O
<	O
40	O
copies	O
/	O
mL	O
at	O
screening	O
and	O
<	O
150	O
copies	O
/	O
mL	O
consistently	O
for	O
≥	O
3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
atazanavir	O
/r	O
and	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
were	O
randomized	O
to	O
continue	O
atazanavir	O
/	O
ritonavir	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
atazanavir	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
backbone	O
.	O

The	O
primary	O
outcome	O
was	O
proportion	O
of	O
subjects	B:C0080105
without	O
treatment	O
failure	I:C0162643
(	O
regimen	O
switch	O
or	O
VL	O
>	O
200	O
copies	O
/	O
mL	O
twice	O
consecutively	O
)	O
at	O
48	O
weeks	O
.	O

The	O
primary	O
outcome	O
was	O
proportion	O
of	O
subjects	O
without	O
treatment	B:C0162643
failure	I:C0162643
(	O
regimen	O
switch	O
or	O
VL	O
>	O
200	O
copies	O
/	O
mL	O
twice	O
consecutively	O
)	O
at	O
48	O
weeks	O
.	O

The	O
primary	O
outcome	O
was	O
proportion	O
of	O
subjects	O
without	O
treatment	O
failure	I:C0162643
(	O
regimen	B:C0040808
switch	O
or	O
VL	O
>	O
200	O
copies	O
/	O
mL	O
twice	O
consecutively	O
)	O
at	O
48	O
weeks	O
.	O

Fifty	O
participants	B:C0679646
(	O
46	O
male	O
,	O
median	O
age	O
47	O
years	O
)	O
were	O
randomized	O
,	O
25	O
to	O
each	O
arm	O
.	O

Fifty	O
participants	O
(	O
46	O
male	O
,	O
median	O
age	O
47	O
years	O
)	O
were	O
randomized	B:C0034656
,	O
25	O
to	O
each	O
arm	O
.	O

atazanavir	B:C1145759
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	O
438	O
ng	O
/	O
mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	O
124	O
ng	O
/	O
mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	O
at	O
week	O
48	O
(	O
median	O
38	O
μmol	O
/	O
L	O
and	O
28	O
μmol	O
/	O
L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

atazanavir	O
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	B:C0549183
438	O
ng	O
/	O
mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	O
124	O
ng	O
/	O
mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	O
at	O
week	O
48	O
(	O
median	O
38	O
μmol	O
/	O
L	O
and	O
28	O
μmol	O
/	O
L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

atazanavir	O
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	O
438	O
ng	O
/	O
mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	B:C0549183
124	O
ng	O
/	O
mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	O
at	O
week	O
48	O
(	O
median	O
38	O
μmol	O
/	O
L	O
and	O
28	O
μmol	O
/	O
L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

atazanavir	O
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	O
438	O
ng	O
/	O
mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	O
124	O
ng	O
/	O
mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	B:C0005437
at	O
week	O
48	O
(	O
median	O
38	O
μmol	O
/	O
L	O
and	O
28	O
μmol	O
/	O
L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

atazanavir	O
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	O
438	O
ng	O
/	O
mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	O
124	O
ng	O
/	O
mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	O
at	O
week	O
48	O
(	O
median	B:C0549183
38	O
μmol	O
/	O
L	O
and	O
28	O
μmol	O
/	O
L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
decreased	O
in	O
the	O
control	O
arm	O
(	O
p	O
=	O
0.007	O
)	O
,	O
but	O
did	O
not	O
change	I:C0442739
in	O
the	O
switch	O
arm	O
.	O

Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
Estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
decreased	O
in	O
the	O
control	O
arm	O
(	O
p	O
=	O
0.007	O
)	O
,	O
but	O
did	O
not	O
change	I:C0442739
in	O
the	O
switch	O
arm	O
.	O

Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
decreased	O
in	O
the	O
control	O
arm	O
(	O
p	O
=	O
0.007	O
)	O
,	O
but	O
did	O
not	B:C0442739
change	I:C0442739
in	O
the	O
switch	O
arm	O
.	O

At	O
week	O
48	O
,	O
Estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	O
glucose	I:C0202045
,	O
C	O
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	O
parameters	O
.	O

At	O
week	O
48	O
,	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	B:C0549183
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	O
glucose	I:C0202045
,	O
C	O
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	O
parameters	O
.	O

At	O
week	O
48	O
,	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	B:C0549183
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	O
glucose	I:C0202045
,	O
C	O
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	O
parameters	O
.	O

At	O
week	O
48	O
,	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	B:C0202045
glucose	I:C0202045
,	O
C	O
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	O
parameters	O
.	O

At	O
week	O
48	O
,	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	O
glucose	I:C0202045
,	O
C	B:C0006560
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	O
parameters	O
.	O

At	O
week	O
48	O
,	O
Estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL	O
/	O
min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL	O
/	O
min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	O
glucose	I:C0202045
,	O
C	O
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
lipid	B:C0023779
parameters	O
.	O

Switching	O
from	O
atazanavir	B:C1145759
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	B:C0292818
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	B:C1145759
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	B:C0040808
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	B:C0005437
and	O
renal	O
function	I:C0232804
.	O

Switching	O
from	O
atazanavir	O
/	O
ritonavir	O
to	O
unboosted	O
atazanavir	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
-	O
containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	B:C0232804
function	I:C0232804
.	O

